To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis
Age 18 and above.
Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.
Liver and kidney function is within acceptable ranges.
Blood parameters, including complete blood count, coagulation function, and platelet count, are within acceptable ranges.
History of allergy to JAK inhibitors.
Pregnant or breastfeeding women.
Severe infectious conditions.
History of central nervous system demyelinating diseases.
Peng Zhang
Lead sponsor
Fujian Provincial Hospital
Sponsor institution